Weight Loss & MetabolicModerate Evidence

Eloralintide Peptide Therapy

Benefits, Side Effects, Cost & Protocols

Eloralintide peptide molecular structure diagram from PubChem

Eloralintide is an investigational dual amylin and calcitonin receptor agonist being studied for weight management. It works by reducing appetite and slowing gastric emptying through amylin-pathway mechanisms that complement GLP-1-based therapies.

ByChris Riley(CFA)&Alex Evans, PharmD, MBA(PharmD, MBA)|Updated August 23, 2026

Clinically Reviewed

Reviewed by Alex Evans, PharmD, MBA · Updated August 2026

Evidence-Based

Sourced from FDA, PubMed & ClinicalTrials.gov · View sources

FDA Status

Research Only Not currently approved for human use in the US. Available as a research compound. Not eligible for compounding.

Evidence

Moderate Evidence

How Eloralintide Works

Amylin receptor agonist that promotes satiety and reduces food intake through a pathway distinct from GLP-1 signaling.

Eloralintide FAQ

What is ELORALINTIDE?

Eloralintide (LY3841136) is an investigational amylin receptor agonist being developed by Eli Lilly for weight management. It targets the amylin pathway, which is distinct from GLP-1 approaches.

How does ELORALINTIDE work?

Amylin receptor agonist that promotes satiety and reduces food intake through a pathway distinct from GLP-1 signaling.

Is ELORALINTIDE legal to buy?

ELORALINTIDE is sold as a research chemical for laboratory use only. It is not approved for human use by the FDA. Regulations vary by jurisdiction.

Where can I buy ELORALINTIDE?

ELORALINTIDE is available as a research compound from verified online vendors. Always verify third-party testing before purchasing.

What category does ELORALINTIDE belong to?

ELORALINTIDE is primarily classified as a weight loss & metabolic peptide. Peptides researched for their effects on weight management, fat metabolism, appetite regulation, and metabolic enhancement. This category includes GLP-1 agonists, dual/triple agonists, and other metabolic peptides.

What are the research benefits of ELORALINTIDE?

ELORALINTIDE has been studied for: Weight loss potential, Appetite regulation via amylin pathway, Novel mechanism of action. Eli Lilly investigational compound. Targets amylin pathway distinct from GLP-1.

Key Studies

8 total on PubMed0

Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept

Bhattachar S, Tham LS, Tidemann-Miller B et al

Diabetes Obes Metab · Diabetes Obes MetabPhase 1

Eloralintide, a long-acting amylin agonist, shows proof of concept for obesity

Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial

Billings LK, Hsia S, Bays H et al

LancetPhase 2

Eloralintide demonstrates efficacy in obesity treatment in phase 2 randomized trial

Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept

Briere DA, Qu H, Lansu K et al

Mol Metab · Mol Metab

Eloralintide, a novel amylin receptor agonist, shows potential for obesity treatment

Eloralintide Compound Data

Molecular Formula

C201H319N49O65S2

Molecular Weight

4526 g/mol

IUPAC Name

20-[[4-[[4-[[5-[[1-[2-[[2-[[4-amino-2-[[4-amino-2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[2-[[2-[[5-amino-2-[[2-[[2-[2-[[20-[(4-amino-4-carboxy-butanoyl)amino]-17-(2-amino-2-oxo-ethyl)-8,14-bis(1-hydroxyethyl)-11-methyl-7,10,13,16,19-pentaoxo-1,3-dithia-6,9,12,15,18-pentazacyclohenicosane-5-carbonyl]amino]propanoylamino]-3-hydroxy-butanoyl]amino]acetyl]amino]pentanoyl]amino]-4-methyl-pentanoyl]amino]propanoylamino]-4-carboxy-butanoyl]amino]-2-methyl-3-phenyl-propanoyl]amino]-4-methyl-pentanoyl]amino]-3-methyl-butanoyl]amino]-5-guanidino-pentanoyl]amino]-3-hydroxy-propanoyl]amino]-3-hydroxy-propanoyl]amino]-4-oxo-butanoyl]-methyl-amino]-4-oxo-butanoyl]amino]-3-phenyl-propanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-6-[[1-[2-[2-[[1-[[1-[[1-[[2-[[2-[[3-amino-1-[[1-[[2-amino-1-[(4-hydroxyphenyl)methyl]-2-oxo-ethyl]carbamoyl]-2-hydroxy-propyl]carbamoyl]-3-oxo-propyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]amino]-2-oxo-ethyl]carbamoyl]-2-methyl-propyl]carbamoyl]-3-carboxy-propyl]carbamoyl]-2-hydroxy-propyl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]-3-methyl-butyl]amino]-6-oxo-hexyl]amino]-1-carboxy-4-oxo-butyl]amino]-1-carboxy-4-oxo-butyl]amino]-20-oxo-icosanoic acid

View full compound on PubChem

Eloralintide News

Eloralintide: A selective alternative targeting the amylin receptor for obesity management - the-innovation.org

the-innovation.org · 2 months ago

Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting - PR Newswire

PR Newswire · 1 month ago

New GLP-1 alternative, eloralintide, leads to 20% weight loss in trial - Medical News Today

Medical News Today · 9 months ago

Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR Agon - PR Newswire

PR Newswire · 1 month ago

Challenging Eli Lilly! Ascletis Pharma's Oral Weight-Loss Drug Candidate ASC39 Shows Promising Preclinical Data, Plans to Submit FDA Application in Q3 - finance.biggo.com

finance.biggo.com · 5 months ago

News aggregated via Google News. Inclusion does not imply endorsement.

Medical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. Peptide therapies have not been evaluated by the FDA for most listed indications.All prices shown are estimates based on publicly available data and may not reflect current pricing — providers and brands set their own prices and can change them at any time. Always verify pricing directly with the provider before purchasing. Consult a licensed healthcare provider before starting any peptide protocol.

Ready to explore Eloralintide with a provider?

Take our 2-minute quiz to get matched with a board-certified provider specializing in Eloralintide.

Take the Quiz →